<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908282</url>
  </required_header>
  <id_info>
    <org_study_id>REMODES-DE-2015-12</org_study_id>
    <nct_id>NCT02908282</nct_id>
  </id_info>
  <brief_title>Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye</brief_title>
  <acronym>REMOTOP</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of REMOGEN® OMEGA in reducing
      Dry Eye Syndrome (DES) symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI©) questionnaire</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear film stability</measure>
    <time_frame>Week 4</time_frame>
    <description>Tear film breakup time (unit: seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OSDI questionnaire</measure>
    <time_frame>Day 0, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear film stability</measure>
    <time_frame>Day 0, Week 12</time_frame>
    <description>Tear film breakup time (unit: seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity (best corrected)</measure>
    <time_frame>Day 0, Week 4, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TearLab osmolarity test</measure>
    <time_frame>Day 0, Week 4, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation marker matrix metalloproteinase 9 (MMP9)</measure>
    <time_frame>Day 0, Week 4, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid-parallel conjunctival fold (LIPCOF) grading</measure>
    <time_frame>Day 0, Week 4, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal staining</measure>
    <time_frame>Day 0, Week 4, Week 12</time_frame>
    <description>Oxford grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear volume</measure>
    <time_frame>Day 0, Week 4, Week 12</time_frame>
    <description>Schirmer test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining</measure>
    <time_frame>Day 0, Week 4, Week 12</time_frame>
    <description>Oxford grading scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>PUFA (polyunsaturated fatty acids)-group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>REMOGEN OMEGA: Usage according to instructions for use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C (control)-group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Povidone: Usage according to instructions for use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REMOGEN OMEGA</intervention_name>
    <description>Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.</description>
    <arm_group_label>PUFA (polyunsaturated fatty acids)-group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Povidone</intervention_name>
    <description>Artificial tears: preservative-free eye drops containing 2% povidone.</description>
    <arm_group_label>C (control)-group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient between 18 and 80 years of age and in good general health
             condition.

          -  Signed written informed consent.

          -  Existence of moderate to severe DES symptoms defined as Break-up time (TBUT) ≤ 10 s
             (mean of 3 consecutive measurements) and OSDI questionnaire ≥ 20.

        Exclusion Criteria:

          -  Contraindication for the use of the products (e.g. hypersensitivity to the
             constituents of the test products) or any study procedure.

          -  Concomitant or previous participation in a clinical investigation within the last 3
             months.

          -  Concomitant therapies/manipulations that affect either the tear film, tear secretion
             or ocular surface integrity or would alter the effect of the devices being evaluated.

          -  Concurrent (systemic) DES-associated diseases that are not on a stable therapy since
             at least 1 month (therapy not expected to change)

          -  Glaucoma that is not on a stable dosage since at least 2 weeks (therapy not expected
             to change)

          -  Any diseases or characteristics judged by the investigator to be incompatible with the
             assessments and/or procedures for the study evaluation

          -  Pregnant or lactating females.

          -  Participants of childbearing age who do not use adequate methods of birth control.

          -  Subjects unable to understand the informed consent or having a high probability of
             noncompliance to the study procedures and/or non-completion of the study according to
             investigator's judgment (e.g. illiteracy, insufficient knowledge of local language).

          -  Subjects not capable of contracting and of understanding the nature, risks,
             significance and implications of the clinical investigation and unable to form a
             rational intention in the light of these facts.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kaercher, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxis Dr. Thomas Kaercher</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr. Kaercher</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Prof. Dr. Anselm Kampik &amp; Kollegen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenzentrum Olching</name>
      <address>
        <city>Olching</city>
        <state>Bavaria</state>
        <zip>82140</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenheilkunde Lindenthal</name>
      <address>
        <city>Köln-Lindenthal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Flamm &amp; Böker: Augenärzte am Tibarg</name>
      <address>
        <city>Hamburg</city>
        <zip>22459</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tear film</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>eye drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

